US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist

34.270
+0.220+0.65%

Close Jan 24 16:00 ET

34.270
0.0000.00%

Post 20:01 ET

69.92BMarket Cap22.85P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

GlaxoSmithKline Q4 2024 Estimates Date

Currency：USDFeb 5, 2025

	Estimate	YoY
Revenue	9.73B	-5.11%
EPS	0.51	+131.90%

Analyst Rating

Hold

Dec 31, 2024

GlaxoSmithKline Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 7.444B	--
Feb 5, 2025	2024/Q4	-- / 7.751B	--
Oct 30, 2024	2024/Q3	8.012B / 8.007B	--
Jul 31, 2024	2024/Q2	7.884B / 7.493B	--
May 1, 2024	2024/Q1	7.363B / 7.060B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 7.444B--

Feb 5, 20252024/Q4-- / 7.751B--

Oct 30, 20242024/Q38.012B / 8.007B--

Jul 31, 20242024/Q27.884B / 7.493B--

May 1, 20242024/Q17.363B / 7.060B--

Unlock Free Earnings Estimates

Open Account

GlaxoSmithKline Earnings Reports

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

Oct 30, 2024 11:27 ET

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

Jul 31, 2024 12:31 ET

6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

May 1, 2024 12:34 ET

GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

Mar 5, 2024 13:13 ET

Trending Stocks

Symbol Mini Chart % Chg

Collegium Pharmaceutical

Unlock the Full List

Analysis

Analyst Rating

Updated: Dec 31, 2024

Hold

Buy
20.00%
Hold
60.00%
Sell
20.00%

Price Target

No Data